The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC).
Nathan A. Pennell
Disclosure not yet available
Sujith R. Kalmadi
Disclosure not yet available
Marc A. Shapiro
Disclosure not yet available
Hamed Daw
Disclosure not yet available
Cristina P. Rodriguez
Disclosure not yet available
Abdo S. Haddad
Disclosure not yet available
Tara Rich
Disclosure not yet available
Julia Samsa
Disclosure not yet available
Paul Elson
Disclosure not yet available
Patrick C. Ma
Disclosure not yet available
Afshin Dowlati
Disclosure not yet available